Colorectal cancer remains a major cause of morbidity and mortality worldwide despite substantial improvement in the standard of care. Although surgical resection in selected patients may potentially be curative, systemic therapy is the only choice of treatment for most patients with metastatic colorectal cancer. Anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody has established its role in the systemic therapy of metastatic colorectal cancer through multiple well-designed clinical trials and yet, the optimal use of anti-EGFR monoclonal antibody is undefined. This article serves to review the available evidence for anti-EGFR monoclonal antibodies and to speculate optimal strategy for their uses.
展开▼
机译:Retraction statement: ‘Formin‐like2 regulates Rho/ROCK pathway to promote actin assembly and cell invasion of colorectal cancer’ by Yuanfeng Zeng Huijun Xie Yudan Qiao Jianmei Wang Xiling Zhu Guoyang He Yuling Li Xiaoli Ren Feifei Wang Li Liang and Yanqing Ding